Literature DB >> 34409582

Implications of Antimuscarinic Autoantibodies in Postural Tachycardia Syndrome.

Hongliang Li1, Gege Zhang1, Elizabeth Forsythe1, Luis E Okamoto2, Xichun Yu3.   

Abstract

Functional autoantibodies directed to the M2 muscarinic acetylcholine receptor (M2R) could affect the heart rate directly by altering cardiac M2R activity and/or indirectly by changing vagal-mediated cardiac M2R activity. We measured M2R autoantibody activity in sera from 10 subjects with postural tachycardia syndrome (POTS) and 5 healthy control subjects using a cell-based bioassay. Half of the POTS subjects demonstrated presence of elevated M2R autoantibody activity, while no significant M2R autoantibody activity was found in the healthy subjects. Serum-derived immunoglobulin G (IgG) from antibody-positive POTS patients induced a dose-dependent activation of M2R, which was blocked by the muscarinic antagonist atropine. Moreover, antibody-positive POTS IgG decreased the responsiveness to oxotremorine, an orthosteric muscarinic agonist, indicating an indirect inhibitory effect. These data suggest that M2R autoantibodies may contribute to the pathophysiology of POTS by increasing the normal vagal withdrawal during upright posture through its negative allosteric modulation of M2R activity. M2 muscarinic receptor-activating autoantibodies are present in a subgroup of patients with POTS and act as a negative allosteric modulator of the orthosteric ligand response.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Activating autoantibody; M2 muscarinic acetylcholine receptor; Postural tachycardia syndrome

Mesh:

Substances:

Year:  2021        PMID: 34409582      PMCID: PMC8854442          DOI: 10.1007/s12265-021-10167-z

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   3.216


  5 in total

1.  2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope.

Authors:  Robert S Sheldon; Blair P Grubb; Brian Olshansky; Win-Kuang Shen; Hugh Calkins; Michele Brignole; Satish R Raj; Andrew D Krahn; Carlos A Morillo; Julian M Stewart; Richard Sutton; Paola Sandroni; Karen J Friday; Denise Tessariol Hachul; Mitchell I Cohen; Dennis H Lau; Kenneth A Mayuga; Jeffrey P Moak; Roopinder K Sandhu; Khalil Kanjwal
Journal:  Heart Rhythm       Date:  2015-05-14       Impact factor: 6.343

2.  Impairment of agonist-induced M2 muscarinic receptor activation by autoantibodies from chagasic patients with cardiovascular dysautonomia.

Authors:  Sabrina P Beltrame; Laura C Carrera Páez; Sergio R Auger; Ahmad H Sabra; Claudio R Bilder; Claudia I Waldner; Juan C Goin
Journal:  Clin Immunol       Date:  2020-01-16       Impact factor: 3.969

Review 3.  Autoimmunity in postural orthostatic tachycardia syndrome: Current understanding.

Authors:  Steven Vernino; Lauren E Stiles
Journal:  Auton Neurosci       Date:  2018-04-26       Impact factor: 3.145

4.  Postural Orthostatic Tachycardia Syndrome Is Associated With Elevated G-Protein Coupled Receptor Autoantibodies.

Authors:  William T Gunning; Heather Kvale; Paula M Kramer; Beverly L Karabin; Blair P Grubb
Journal:  J Am Heart Assoc       Date:  2019-09-09       Impact factor: 5.501

5.  Autoimmune basis for postural tachycardia syndrome.

Authors:  Hongliang Li; Xichun Yu; Campbell Liles; Muneer Khan; Megan Vanderlinde-Wood; Allison Galloway; Caitlin Zillner; Alexandria Benbrook; Sean Reim; Daniel Collier; Michael A Hill; Satish R Raj; Luis E Okamoto; Madeleine W Cunningham; Christopher E Aston; David C Kem
Journal:  J Am Heart Assoc       Date:  2014-02-26       Impact factor: 5.501

  5 in total
  1 in total

1.  Transcutaneous vagus nerve stimulation attenuates autoantibody-mediated cardiovagal dysfunction and inflammation in a rabbit model of postural tachycardia syndrome.

Authors:  Jielin Deng; Hongliang Li; Yankai Guo; Gege Zhang; Hayley Fischer; Stavros Stavrakis; Xichun Yu
Journal:  J Interv Card Electrophysiol       Date:  2022-02-04       Impact factor: 1.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.